Dihydroergotamine Injection

Major

Dihydroergotamine Injection Lumacaftor Reduced exposure to CYP3A substrate Details Dihydroergotamine Injection Mavorixafor Xolremdi Increased CYP3A4 substrate with NTI exposure and an increased risk of CYP3A4 with NTI-related adverse events Details Dihydroergotamine Injection Mitapivat Aqvesme Reduced CYP3A substrate exposure Details Dihydroergotamine Injection Mitotane Lysodren Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI exposure Details Dihydroergotamine Injection Mobocertinib Exkivity Decreased plasma concentrations of the CYP3A substrate, which may result in serious therapeutic failure Details Dihydroergotamine Injection Netupitant Increased exposure of CYP3A4 substrate Details Dihydroergotamine Injection Nilotinib Increased dihydroergotamine exposure and an increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Dihydroergotamine Injection Nirogacestat Ogsiveo Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse effects Details Dihydroergotamine Injection Octreotide Bynfezia Increased exposure of CYP3A4 substrates with narrow therapeutic index Details Dihydroergotamine Injection Omaveloxolone Skyclarys Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Dihydroergotamine Injection Pacritinib Vonjo® Reduced CYP3A4 substrate with NTI exposure and reduced efficacy of CYP3A4 substrate with NTI Details Dihydroergotamine Injection Palbociclib Ibrance Increased exposure to CYP3A substrates with a narrow therapeutic index Details Dihydroergotamine Injection Pazopanib Votrient Increased dihydroergotamine concentrations and risk of ergot toxicity Details Dihydroergotamine Injection Phenobarbital Fidoquel Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Dihydroergotamine Injection Pirtobrutinib Jaypirca Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-related adverse effects Details Dihydroergotamine Injection Primidone Mysoline Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Dihydroergotamine Injection Propatyl Nitrate Increased risk of ergotism Details Dihydroergotamine Injection Propranolol Hemangeol Increased risk of coronary artery vasospasm Details Dihydroergotamine Injection Ranolazine Aspruzyo Increased exposure of CYP3A4 substrate Details Dihydroergotamine Injection Relacorilant Lifyorli Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse reactions Details Dihydroergotamine Injection Repotrectinib Augtyro Reduced CYP3A4 substrates exposure and reduced efficacy of CYP3A4 substrates Details Dihydroergotamine Injection Ritlecitinib Litfulo Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Dihydroergotamine Injection Schizandra Increased dihydroergotamine exposure and an increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Dihydroergotamine Injection Selpercatinib Retevmo Increased substrate exposure and an increased risk for adverse effects Details Dihydroergotamine Injection Sevabertinib Hyrnuo Increased CYP3A substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details Dihydroergotamine Injection Sibutramine An increased risk of serotonin syndrome (hypertension, hyperthermia, myoclonus, mental status changes) Details Dihydroergotamine Injection Sotorasib Lumakras Reduced exposure to CYP3A substrate and an increased risk of therapeutic failure Details Dihydroergotamine Injection Stiripentol Diacomit Increased dihydroergotamine exposure and an increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Dihydroergotamine Injection Suzetrigine Journavx Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Dihydroergotamine Injection Taurursodiol Decreased exposure of the CYP3A4 substrate Details Dihydroergotamine Injection Tazemetostat Tazverik Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Dihydroergotamine Injection Tocilizumab Actemra Reduced CYP3A4 substrate with NTI exposure and reduced efficacy of CYP3A4 substrate with NTI Details Dihydroergotamine Injection Tovorafenib Ojemda Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Dihydroergotamine Injection Treosulfan Grafapex Increased CYP3A4 substrate exposure and an increased risk of CYP3A4 substrate-related adverse and serious life-threatening toxicit... Details Dihydroergotamine Injection Verapamil Calan Increased dihydroergotamine exposure and an increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Dihydroergotamine Injection Vonoprazan Voquezna Increased CYP3A substrates exposure Details Dihydroergotamine Injection Vorasidenib Voranigo Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Dihydroergotamine Injection Voxelotor Oxbryta Increased dihydroergotamine exposure and an increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Dihydroergotamine Injection Zileuton Zyflo Increased ergot derivatives exposure and an increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details